High-content molecular profiling of T-cell therapy in oncology.
Recent clinical data have revealed the remarkable potential for T-cell-modulating agents to induce potent and durable responses in a subset of cancer patients. In this review, we discuss molecular approaches, platforms, and strategies that enable a broader interrogation of the activity of agents that modulate the activity of tumor-specific T cells, to more comprehensively understand how and why the agents succeed and fail, as well as examples of data sets generated in clinical trials that have provided important insights into the biological activity of T-cell therapies and that support further rational development of this exciting treatment modality.
Department of Cancer Immunobiology, Eli Lilly and Company , New York, New York, USA.
Ruslan
R
Novosiadly
Department of Cancer Immunobiology, Eli Lilly and Company , New York, New York, USA.
Michael
M
Kalos